Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells
Shinji Oki, … , Takashi Yamamura, Sachiko Miyake
Shinji Oki, … , Takashi Yamamura, Sachiko Miyake
Published June 1, 2004
Citation Information: J Clin Invest. 2004;113(11):1631-1640. https://doi.org/10.1172/JCI20862.
View: Text | PDF
Article Immunology

The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells

  • Text
  • PDF
Abstract

OCH, a sphingosine-truncated analog of α-galactosylceramide (αGC), is a potential therapeutic reagent for a variety of Th1-mediated autoimmune diseases through its selective induction of Th2 cytokines from natural killer T (NKT) cells. We demonstrate here that the NKT cell production of IFN-γ is more susceptible to the sphingosine length of glycolipid ligand than that of IL-4 and that the length of the sphingosine chain determines the duration of NKT cell stimulation by CD1d-associated glycolipids. Furthermore, IFN-γ production by NKT cells requires longer T cell receptor stimulation than is required for IL-4 production by NKT cells stimulated either with immobilized mAb to CD3 or with immobilized “αGC-loaded” CD1d molecules. Interestingly, transcription of IFN-γ but not that of IL-4 was sensitive to cycloheximide treatment, indicating the intrinsic involvement of de novo protein synthesis for IFN-γ production by NKT cells. Finally, we determined c-Rel was preferentially transcribed in αGC-stimulated but not in OCH-stimulated NKT cells and was essential for IFN-γ production by activated NKT cells. Given the dominant immune regulation by the remarkable cytokine production of ligand-stimulated NKT cells in vivo, in comparison with that of (antigen-specific) T cells or NK cells, the current study confirms OCH as a likely therapeutic reagent for use against Th1-mediated autoimmune diseases and provides a novel clue for the design of drugs targeting NKT cells.

Authors

Shinji Oki, Asako Chiba, Takashi Yamamura, Sachiko Miyake

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Kinetic analysis of NKT cell activation and cytokine production after gl...
Kinetic analysis of NKT cell activation and cytokine production after glycolipid stimulation. (A) Differential production of IFN-γ and IL-4 by activated NKT cells. CD3+NK1.1+ NKT cells and conventional CD3+NK1.1_ T cells were purified from liver mononuclear cells by cell sorting. The sorted cells were stimulated with immobilized mAb to CD3 for the time indicated on the x axis and were then removed and recultured on a fresh culture plate without anti-CD3 stimulation for up to 72 hours from the start of the anti-CD3 stimulation. Incorporation of [3H]thymidine (1 ∝Ci/well) during the final 16 hours of the culture was assessed (left), and culture supernatants were analyzed for the production of IL-4 (center) and IFN-γ (right) by ELISA. One experiment representative of three independent experiments with similar results is shown. (B) NKT cells purified from liver mononuclear cells were stimulated with plates coated with DimerX I loaded with αGC and were analyzed as shown in A. (C) NKT cells purified from liver mononuclear cells were stimulated as shown in A in the presence [CsA(+)] or absence [CsA(_)] of CsA (1 ∝g/ml). Culture supernatants were analyzed for the production of IL-4 and IFN-γ by ELISA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts